Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

Purpose The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy. Methods A total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizuma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gastrointestinal cancer 2019-06, Vol.50 (2), p.214-220
Hauptverfasser: Artaç, Mehmet, Korkmaz, Levent, Coşkun, Hasan Şenol, Dane, Faysal, Karabulut, Bülent, Karaağaç, Mustafa, Çabuk, Devrim, Karabulut, Senem, Aykan, Nuri Faruk, Doruk, Hatice, Avcı, Nilüfer, Turhal, Nazım Serdar
Format: Artikel
Sprache:eng
Schlagworte:
Cancer Research
Gastroenterology
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Original Research
Radiotherapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy. Methods A total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizumab were studied. Patients were grouped as obese (BMI levels > 30) or non-obese (BMI levels
ISSN:1941-6628
1941-6636
DOI:10.1007/s12029-017-0047-2